Both male and female obese ZSF1 rats develop cardiac dysfunction in obesity-induced heart failure with preserved ejection fraction.
Animals
Blood Pressure
/ physiology
Collagen
/ metabolism
Diastole
/ physiology
Disease Models, Animal
Echocardiography
Female
Heart Failure
/ diagnostic imaging
Male
Metabolic Syndrome
/ complications
Myocardium
/ metabolism
Obesity
/ complications
Rats
Rats, Inbred SHR
Rats, Zucker
Sex Characteristics
Stroke Volume
/ physiology
Thinness
/ physiopathology
Ventricular Remodeling
/ physiology
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
08
2019
accepted:
14
04
2020
entrez:
7
5
2020
pubmed:
7
5
2020
medline:
1
8
2020
Statut:
epublish
Résumé
Heart failure with a preserved ejection fraction (HFpEF) is associated with multiple comorbidities, such as old age, hypertension, type 2 diabetes and obesity and is more prevalent in females. Although the male obese ZSF1 rat has been proposed as a suitable model to study the development of diastolic dysfunction and early HFpEF, studies in female animals have not been performed yet. Therefore, we aimed to characterize the cardiac phenotype in female obese ZSF1 rats and their lean counterparts. Additionally, we aimed to investigate whether differences exist in disease progression in obese male and female ZSF1 rats. Therefore, male and female ZSF1 rats, lean as well as obese (N = 6-9/subgroup), were used. Every two weeks, from 12 to 26 weeks of age, systolic blood pressure and echocardiographic measurements were performed, and venous blood was sampled. Female obese ZSF1 rats, as compared to female lean ZSF1 rats, developed diastolic dysfunction with cardiac hypertrophy and fibrosis in the presence of severe dyslipidemia, increased plasma growth differentiation factor 15 and mild hypertension, and preservation of systolic function. Although obese female ZSF1 rats did not develop hyperglycemia, their diastolic dysfunction was as severe as in the obese males. Taken together, the results from the present study suggest that the female obese ZSF1 rat is a relevant animal model for HFpEF with multiple comorbidities, suitable for investigating novel therapeutic interventions.
Identifiants
pubmed: 32374790
doi: 10.1371/journal.pone.0232399
pii: PONE-D-19-24353
pmc: PMC7202634
doi:
Substances chimiques
Collagen
9007-34-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0232399Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Exp Physiol. 2017 Aug 1;102(8):911-923
pubmed: 28543947
J Cell Mol Med. 2019 Oct;23(10):6666-6678
pubmed: 31368189
Am J Physiol Regul Integr Comp Physiol. 2010 Mar;298(3):R815-23
pubmed: 20032261
J Cardiovasc Pharmacol. 2011 Apr;57(4):469-78
pubmed: 21283019
Kidney Int. 1998 Jan;53(1):130-5
pubmed: 9453009
Nat Rev Cardiol. 2017 Oct;14(10):591-602
pubmed: 28492288
Circ Heart Fail. 2016 Oct;9(10):
pubmed: 27682440
Eur J Heart Fail. 2010 Dec;12(12):1309-16
pubmed: 20837635
Lab Anim. 2012 Jan;46(1):40-5
pubmed: 22008848
Med Sci Monit. 2018 Jul 18;24:4992-4999
pubmed: 30019695
Eur Heart J. 2019 Oct 21;40(40):3297-3317
pubmed: 31504452
Arq Bras Cardiol. 2011 Jul;97(1):65-75
pubmed: 21584478
Cardiology. 1999;91(3):173-83
pubmed: 10516411
Sci Rep. 2018 Feb 5;8(1):2346
pubmed: 29402990
Circulation. 2006 Apr 25;113(16):1966-73
pubmed: 16618817
Eur Heart J. 2013 Jan;34(4):292-9
pubmed: 23053174
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Front Endocrinol (Lausanne). 2017 Jul 17;8:160
pubmed: 28769873
Diabetes Care. 2008 Aug;31(8):1531-3
pubmed: 18477812
J Am Soc Echocardiogr. 2014 Dec;27(12):1275-8
pubmed: 25479898
Sci Rep. 2017 Dec 19;7(1):17823
pubmed: 29259233
Diabetologia. 1995 Feb;38(2):173-9
pubmed: 7713311
Eur J Heart Fail. 2014 May;16(5):535-42
pubmed: 24574260
Eur J Heart Fail. 2011 Jan;13(1):18-28
pubmed: 20685685
Circ Heart Fail. 2016 Apr;9(4):e002760
pubmed: 27056881
PLoS One. 2012;7(12):e51334
pubmed: 23236474
Am J Physiol Heart Circ Physiol. 2015 Jun 15;308(12):H1556-63
pubmed: 25862827
Eur J Heart Fail. 2012 Nov;14(11):1249-56
pubmed: 22843564
Eur Heart J. 2011 Mar;32(6):670-9
pubmed: 21138935
Eur J Heart Fail. 2018 Feb;20(2):216-227
pubmed: 29148148
Atherosclerosis. 2000 Feb;148(2):231-41
pubmed: 10657558
Physiol Rev. 2017 Jan;97(1):1-37
pubmed: 27807199
Neth Heart J. 2016 Apr;24(4):275-86
pubmed: 26936157
Methods Mol Med. 2003;86:29-46
pubmed: 12886760
Mech Ageing Dev. 1991 Jun 14;59(1-2):197-213
pubmed: 1890883
Cardiovasc Res. 2018 Jun 1;114(7):954-964
pubmed: 29432575
Eur J Heart Fail. 2018 Sep;20(9):1303-1311
pubmed: 29877602
PLoS One. 2014 May 15;9(5):e96452
pubmed: 24831821
Circ Heart Fail. 2018 Mar;11(3):e004153
pubmed: 29535114
Diabetes. 2015 Aug;64(8):2944-56
pubmed: 25784543
Circulation. 2018 Jul 10;138(2):198-205
pubmed: 29986961
Circ Heart Fail. 2013 Nov;6(6):1239-49
pubmed: 24014826
Am J Nephrol. 2016;44(5):339-353
pubmed: 27736813
Am J Physiol Renal Physiol. 2012 Nov 1;303(9):F1253-63
pubmed: 22914779
Eur J Heart Fail. 2012 Feb;14(2):193-201
pubmed: 22253456
Circ Heart Fail. 2010 Jan;3(1):29-34
pubmed: 19917649
J Am Coll Cardiol. 2014 Feb 11;63(5):407-16
pubmed: 24291270
Arch Cardiovasc Dis. 2018 Dec;111(12):766-781
pubmed: 29960837
Eur J Heart Fail. 2017 Mar;19(3):326-336
pubmed: 27995696
Drug Discov Today Dis Models. 2007;4(4):227-232
pubmed: 19081826
Metabolism. 2008 Oct;57(10):1434-44
pubmed: 18803950
Am J Physiol Heart Circ Physiol. 2018 Oct 1;315(4):H934-H949
pubmed: 30004258
J Mol Endocrinol. 2011 Aug 25;47(2):129-43
pubmed: 21673048
Circulation. 2006 Nov 14;114(20):2138-47
pubmed: 17088459
Horm Metab Res. 2014 Oct;46(11):774-81
pubmed: 24983383